QL
ELVN icon

Quarry LP’s Enliven Therapeutics ELVN Stock Holding History

Quarry LP’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+4,033
New +$171K 0.02% 310
2024
Q3 		– Sell
-52
Closed -$1.22K – 1755
2024
Q2 		$1.22K Buy
+52
New +$1.09K ﹤0.01% 1684

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Quarry LP's ELVN Position: Q2 2026 in Review

Quarry LP opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 4,033 shares worth $205K. The stake represents 0.02% of the portfolio and ranks #310 among its holdings. This is a return to the name: Quarry LP previously reported a position in ELVN as recently as Q2 2024.

Quarry LP first reported a position in ELVN in Q2 2024 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Quarry LP held 4,033 shares of Enliven Therapeutics worth $205K as of Q2 2026.
  • Enliven Therapeutics was a new Quarry LP position in Q2 2026.
  • Enliven Therapeutics made up 0.02% of Quarry LP's portfolio in Q2 2026, its #310 holding.
  • Quarry LP first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Quarry LP's 13F filing for Q2 2026, filed 14 Aug 2026.